XML 18 R8.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Condensed Consolidated Financial Statements Detail | 6 Months Ended
--- | ---
Jun. 30, 2017
Condensed Consolidated Financial Statements Detail [Abstract] |
Condensed Consolidated Financial Statements Detail | 3. Condensed Consolidated Financial Statements Detail Cash and Cash Equivalents As of June 30, 2017, cash and cash equivalents consisted of demand deposits of $2.6 million and money market funds of $9.9 million with maturities of less than 90 days at the date of purchase. As of December 31, 2016, cash and cash equivalents consisted of demand deposits of $21.5 million and money market funds of $4.2 million with maturities of less than 90 days at the date of purchase. Trade and Other Receivables, net Trade receivables are stated at their net realizable value. Specific allowances are recorded for doubtful accounts or based on other available information. The Company reviews its exposure to accounts receivable, including the requirement for allowances based on management’s judgment. The Company has not historically experienced any significant losses. Trade and other receivables consisted of the following (in thousands):
|  | June 30, |  |  | December 31, |
|  | 2017 |  |  | 2016 |
Trade receivables, net |  | $ | 10,546 |  |  | $ | 474 |
Other receivables |  |  | 85 |  |  |  | 92 |
Trade and other receivables, net |  | $ | 10,631 |  |  | $ | 566 |
Property and Equipment, net Property and equipment, net consisted of the following (in thousands):
|  | June 30, |  |  | December 31, |
|  | 2017 |  |  | 2016 |
Equipment and furniture |  | $ | 1,921 |  |  | $ | 14,023 |
Leasehold improvements |  |  | 334 |  |  |  | 554 |
|  |  | 2,255 |  |  |  | 14,577 |
Less: Accumulated depreciation and amortization |  |  | (2,021 | ) |  |  | (13,541 | )
Property and equipment, net |  | $ | 234 |  |  | $ | 1,036 |
During the six months ended June 30, 2017, the Company completed the sale of equipment and disposal of certain equipment located in one of its leased facilities for total proceeds of $1.6 million. The total carrying value of the equipment sold and disposed of was $0.4 million. Accordingly, the Company recorded a loss of $88,000 and gain of $1.2 million on the sale and disposal of equipment in the other income (expense), net line of the condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2017, respectively. Accrued and Other Liabilities Accrued and other liabilities consisted of the following (in thousands):
|  | June 30, |  |  | December 31, |
|  | 2017 |  |  | 2016 |
Accrued payroll and other benefits |  | $ | 138 |  |  | $ | 1,582 |
Accrued clinical trial costs |  |  | 389 |  |  |  | 743 |
Accrued incentive compensation |  |  | 134 |  |  |  | — |
Accrued legal and accounting fees |  |  | 641 |  |  |  | 385 |
Other |  |  | 760 |  |  |  | 1,505 |
Total |  | $ | 2,062 |  |  | $ | 4,215 |
Net Income (Loss) Per Share Available to Common Stockholders The following is a reconciliation of the numerator (net income or loss) and the denominator (number of shares) used in the calculation of basic and diluted net income (loss) per share available to common stockholders (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2017 |  |  | 2016 |  |  | 2017 |  |  | 2016 |
Numerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 285 |  |  | $ | (15,160 | ) |  | $ | (10,429 | ) |  | $ | (23,525 | )
Less: Deemed dividend on convertible preferred stock |  |  | — |  |  |  | — |  |  |  | (5,603 | ) |  |  | — |
Less: Allocation of undistributed earnings to participating securities |  |  | (113 | ) |  |  | — |  |  |  | — |  |  |  | — |
Net income (loss) available to common stockholders, basic and diluted |  | $ | 172 |  |  | $ | (15,160 | ) |  | $ | (16,032 | ) |  | $ | (23,525 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares outstanding used for basic net income (loss) per share available to common stockholders |  |  | 7,588 |  |  |  | 6,022 |  |  |  | 7,240 |  |  |  | 6,000 |
Effect of dilutive stock options |  |  | 55 |  |  |  | — |  |  |  | — |  |  |  | — |
Weighted average shares outstanding used for diluted net income (loss) per share available to common stockholders |  |  | 7,643 |  |  |  | 6,022 |  |  |  | 7,240 |  |  |  | 6,000 |
Potentially dilutive securities are excluded from the calculation of diluted net income (loss) per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income (loss) per share available to common stockholders (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2017 |  |  | 2016 |  |  | 2017 |  |  | 2016 |
Convertible preferred stock (as converted) |  |  | — |  |  |  | — |  |  |  | 3,732 |  |  |  | — |
Common stock options and RSUs |  |  | 1,138 |  |  |  | 554 |  |  |  | 1,391 |  |  |  | 544 |
Warrants for common stock |  |  | 19 |  |  |  | 917 |  |  |  | 19 |  |  |  | 914 |
Total |  |  | 1,157 |  |  |  | 1,471 |  |  |  | 5,142 |  |  |  | 1,458 |

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Condensed consolidated financial statements detail. + References No definition available. + Details
Name: | xoma_CondensedConsolidatedFinancialStatementsDetailAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration